itsjustme wrote:Whilst reading about some patents/discoveries on The Mylein Repair Foundation website I found this doctor's name listed as a co-author of a paper. So...he should know something or two...right? But yet I don't know.
You can bet that the makers of Avonex, Rebif and Betaseron don't have this serious adverse effect profile listed in any of their literature. I guess that doesn't make for good potential sales to MS patients and their docs....Having said that, one of the partners of Tysabri is Biogen/IDEC
And Tysabri had double the infection rates of placebo patients during the trials.
Interferon Beta is not exclusive to Avonex. Betaseron and Rebif are also interferon beta immune modulating medications, so Avonex can not be singled out.
[color=blue][size=14]This statement is incorrect. Note that a total of 1617 multiple sclerosis patients in controlled studies received Tysabri. In Studies 1 (monotherapy) and 2 (combo therapy), the rate of any type of infection was approximately 1.5 per patient-year in both TYSABRI®-treated patients and placebo-treated patients. The infections were predominately upper respiratory tract infections, influenza, and urinary tract infections. Therefore, the infection rates were approximately the same in both Tysabri treated patients and patients that received the placebo, not double.
The original data from the Tysari trials showed, if I remember correctly, that the infection rate was just above 3% for users and about 1.5% for placebo
were and still are incorrect.And Tysabri had double the infection rates of placebo patients during the trials
I provided the original data from the Tysabri trials in my post. I therefore stand by my post that your previous commentswere and still are incorrect.And Tysabri had double the infection rates of placebo patients during the trials
Personal opinions and positions will vary, but data won't.
Users browsing this forum: No registered users